Source comparison
What Is Cibinetide Same as ARA-290: Research vs Therapeutic Applications Comparison
Primary Indication Studied Small fiber neuropathy in sarcoidosis, diabetes-related neuropathy, chemotherapy-induced neuropathy Same indications. No formulation difference between names Both names refer to the same compound in the same clinical contexts Dosing
This comparison does not assign a generated winner or score.
- Primary Indication Studied
- Small fiber neuropathy in sarcoidosis, diabetes-related neuropathy, chemotherapy-induced neuropathy
- Same indications. No formulation difference between names
- Both names refer to the same compound in the same clinical contexts
- Dosing Protocol in Trials
- 1mg or 4mg subcutaneous injection daily for 28 days
- Identical. INN assignment does not alter dose ranges studied
- Dosing consistency across nomenclature supports that cibinetide same as ARA-290 molecularly
- Mechanism of Action
- Selective innate repair receptor (IRR) agonist via CD131/EPOR heterodimer
- Identical receptor target and downstream JAK2/STAT3 pathway activation
- No mechanistic difference. Both activate tissue-protective signaling without erythropoiesis
- Regulatory Status
- Investigational compound code used in Phase 1 and early Phase 2 trials
- INN assigned 2014. Indicates advancement toward potential approval but not marketed anywhere
- Neither name indicates FDA approval; both remain investigational as of 2026
- Literature Indexing
- PubMed entries primarily 2011–2014 under 'ARA-290'
- Later publications (2014–2017) use 'cibinetide'; some cross-reference both
- Researchers must search both terms to capture full clinical trial dataset
- This table underscores that cibinetide same as ARA-290 in every measurable parameter. Peptide sequence, receptor target, pharmacokinetics, and clinical application. The nomenclature shift reflects pharmaceutical branding convention, not molecular modification.